Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study

Open access
Sørensen, Rikke, Gislason, Gunnar, Torp-Pedersen, Christian, Olesen, Jonas Bjerring, Fosbøl, Emil L, Hvidtfeldt, Morten W, Karasoy, Deniz, Lamberts, Morten, Charlot, Mette, Køber, Lars, Weeke, Peter, Lip, Gregory Y H, Hansen, Morten Lock · 2013 · BMJ Open

Abstract

Objective: Dabigatran was recently approved for anticoagulation in patients with atrial fibrillation (AF); data regarding real-world use, comparative effectiveness and safety are sparse. Design: Pharmacoepidemiological cohort study. Methods/settings: From nationwide registers, we identified patients with an in-hospital or outpatient-clinic AF diagnosis who claimed a prescription of dabigatran 110 or 150 mg, or vitamin K antagonist (VKA), between 22 August and 31 December 2011. HRs of thromboembolic events (ischaemic stroke, transitory ischaemic attack and peripheral artery embolism) and bleedings were estimated using Cox regression analyses in all patients and stratified by previous VKA use. Results: Overall, 1612 (3.1%) and 1114 (2.1%) patients claimed a prescription of dabigatran 110 and 150 mg, and 49640 (94.8%) of VKA. Patients treated with dabigatran 150 mg were younger with less comorbidity than those treated with dabigatran 110 mg and VKA, as were VKA naïve patients compared with previous VKA users. Recommendations set by the European Medicine Agency (EMA) for dabigatran were met in 90.3% and 55.5% of patients treated with 110 and 150 mg. Patients treated with 150 mg dabigatran, who did not fulfil the recommendations by EMA, were >80 years, patients with liver or kidney disease, patients with previous bleeding. Compared with VKA, the thromboembolic risk associated with dabigatran 110 and 150 mg was HR 3.52 (1.40 to 8.84) and 5.79 (1.81 to 18.56) in previous VKA users, and HR 0.95(0.47 to 1.91) and 1.14(0.60 to 2.16) in VKA naïve patients. Bleeding risk was increased in previous VKA users receiving dabigatran 110 mg, but not in patients with 150 mg dabigatran, nor in the VKA naïve users. Conclusions: Deviations from the recommended use of dabigatran were frequent among patients treated with 150 mg. With cautious interpretation, dabigatran use in VKA naïve patients seems safe. Increased risk of thromboembolism and bleeding with dabigatran among previous VKA users was unexpected and may reflect patient selection and ‘drug switching’ practices.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2013-002758

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 184

Metadata

Authors
Sørensen, R., Gislason, G., Torp-Pedersen, C., Olesen, J. B., Fosbøl, E. L., Hvidtfeldt, M. W., Karasoy, D., Lamberts, M., Charlot, M., Køber, L., Weeke, P., Lip, G. Y. H., & Hansen, M. L.
Venue
BMJ Open
Publisher
BMJ
Published
2013
Volume
3
Issue
5
Pages
e002758
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2042608661
Cited by
184
References
8
FWCI
23.30
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. https://app.cochat.ai/papers/10.1136/bmjopen-2013-002758
The paper
Sørensen, R., Gislason, G., Torp-Pedersen, C., Olesen, J. B., Fosbøl, E. L., Hvidtfeldt, M. W., Karasoy, D., Lamberts, M., Charlot, M., Køber, L., Weeke, P., Lip, G. Y. H., & Hansen, M. L. (2013). Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. https://doi.org/10.1136/bmjopen-2013-002758

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.